Headaches During Tirzepatide Treatment: What the Evidence Shows

What the trial data and official guidance say about headaches on tirzepatide

The Mounjaro Summary of Product Characteristics, published on the electronic Medicines Compendium, lists headache among the commonly reported adverse reactions observed during clinical development. In SURMOUNT-1, the landmark 72-week phase 3 trial involving 2,539 adults with obesity, gastrointestinal effects dominated the side-effect picture, but headache and fatigue also appeared across all active dose groups. The pattern was consistent with what regulators expect from medicines that slow gastric emptying and shift appetite signalling: the body takes time to recalibrate.

The NHS medicines page for tirzepatide confirms headache as a known side effect and places it in the category of effects most likely to settle with time. This matters because it shapes clinical advice: prescribers generally encourage patients to persist through early headaches rather than stopping treatment, provided the headaches remain mild and there are no other concerning features alongside them.

Two mechanisms are thought to contribute. First, GIP and GLP-1 receptor activation affects central appetite and satiety circuits; adjusting to reduced calorie intake can trigger headaches in some people. Second, nausea (itself a very common early effect) can suppress thirst and lead to low fluid intake, making dehydration-related headaches more likely, and our guide to tirzepatide side effects including headache explains both pathways in more detail and points toward the most practical responses.

Practical steps that help most people with headaches on tirzepatide

Hydration is the single most consistent piece of advice from prescribers dealing with this complaint. A question our prescribers hear most weeks is whether paracetamol is safe to take alongside tirzepatide, and for most adults without contraindications, standard-dose paracetamol is an appropriate first choice for a mild headache. Ibuprofen and other NSAIDs are generally used with more caution in people who are also experiencing GI symptoms, so checking with your prescriber before reaching for them is sensible.

Sipping water steadily through the day, rather than trying to drink large amounts quickly when already nauseous, tends to work better for people on tirzepatide. Small, bland meals can reduce the nausea that feeds into dehydration and the headaches that follow, and if you are also dealing with loose stools alongside your other symptoms, our advice on managing diarrhoea during Mounjaro treatment covers practical steps that often help on both fronts. Rest and avoiding screens during an acute headache also help, nothing medically novel, but consistently useful.

Headaches are most common in the first one to two weeks after starting at 2.5 mg and may return briefly after each dose step. For most people they become less frequent and less intense as the weeks pass. If yours are not following that trajectory, telling your prescriber promptly gives them the chance to consider whether the titration pace needs adjusting. Details on the full range of Mounjaro side effects can help you put headache in context alongside the other effects people commonly experience, including burping, which our Mounjaro burping treatment page addresses separately.

When a headache on tirzepatide needs medical attention

Most headaches on tirzepatide do not need anything beyond the steps above. A few situations do. Seek prompt medical help (call 111 or go to A&E) if a headache is sudden and severe in a way that feels unlike any headache you have had before, or if it comes with vision disturbance, confusion, a stiff neck, or persistent vomiting that prevents you from keeping fluids down.

Severe vomiting alongside a bad headache can also signal dehydration serious enough to affect kidney function, which the MHRA's Yellow Card scheme and NHS guidance both identify as a risk to monitor during GLP-1 treatment. If you cannot tolerate any fluids by mouth, that is a reason to seek same-day medical advice rather than waiting to see if things improve. Equally, if headaches are accompanied by significant upper abdominal pain that radiates toward your back, those symptoms should be assessed urgently regardless of any other explanation, given the known association between GLP-1 medicines and pancreatitis highlighted in the MHRA's January 2026 Drug Safety Update.

You can report any suspected side effect, including headache patterns that concern you, through the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting genuinely helps build the post-market safety picture for newer medicines.

Before you start: what to discuss with your prescriber

If you have a history of migraines, cluster headaches or other recurrent headache conditions, mentioning this during your consultation is worthwhile. Tirzepatide is not contraindicated in people with migraine, but a prescriber who knows your history can discuss realistic expectations and, if needed, coordinate with your GP. People who already use prescription migraine medicines may want to flag any potential interaction, and those concerned about longer-term effects such as hair thinning can find relevant guidance on our Mounjaro hair loss treatment page.

The free consultation at nume covers side effects as a standard part of the clinical assessment, a GPhC-registered prescriber reads your answers and history the same day, not a decision made by software. That conversation is a good place to ask about headache risk if you are concerned before starting. You can also read about how our clinical team approaches treatment on our prescriber profile page, and find answers to broader questions on our FAQs. For a fuller picture of what managing treatment looks like day to day, the treatment overview is a practical starting point.